C
Carlos Caldas
Researcher at University of Cambridge
Publications - 573
Citations - 86546
Carlos Caldas is an academic researcher from University of Cambridge. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 122, co-authored 547 publications receiving 73840 citations. Previous affiliations of Carlos Caldas include Institute of Cancer Research & University of Münster.
Papers
More filters
Journal ArticleDOI
Improving breast cancer survival analysis through competition-based multidimensional modeling
Erhan Bilal,Janusz Dutkowski,Justin Guinney,In Sock Jang,Benjamin A. Logsdon,Benjamin A. Logsdon,Gaurav Pandey,Benjamin A. Sauerwine,Yishai Shimoni,Hans Kristian Moen Vollan,Hans Kristian Moen Vollan,Hans Kristian Moen Vollan,Brigham H. Mecham,Oscar M. Rueda,Oscar M. Rueda,Jörg Tost,Christina Curtis,Mariano J. Alvarez,Vessela N. Kristensen,Samuel Aparicio,Anne Lise Børresen-Dale,Carlos Caldas,Andrea Califano,Stephen H. Friend,Trey Ideker,Eric E. Schadt,Gustavo Stolovitzky,Adam A. Margolin +27 more
TL;DR: It is found that machine learning methods combined with molecular features selected based on expert prior knowledge can improve survival predictions compared to current best-in-class methodologies and that ensemble models trained across multiple user submissions systematically outperform individual models within the ensemble.
Journal ArticleDOI
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
Helena M. Earl,Helena M. Earl,Helena M. Earl,Louise Hiller,Anne-Laure Vallier,Shrushma Loi,Karen McAdam,Karen McAdam,Luke Hughes-Davies,Adrian Harnett,Mei-Lin Ah-See,Richard Simcock,Daniel Rea,Sanjay Raj,Pamela Woodings,Mark Harries,Donna L. Howe,Kerry Raynes,Helen B Higgins,Maggie Wilcox,Chris Plummer,Chris Plummer,Janine Mansi,Ioannis Gounaris,Betania Mahler Araujo,Elena Provenzano,Elena Provenzano,Anita Chhabra,Jean Abraham,Jean Abraham,Jean Abraham,Carlos Caldas,Peter Hall,Christopher McCabe,Claire Hulme,Claire Hulme,David Miles,Andrew M Wardley,David Cameron,Janet A. Dunn,Roshan Agarwal,Hafiz Algurafi,Rozenn Allerton,Caroline Archer,Anne C Armstrong,Catherine Bale,Lisa H Barraclough,Urmila Barthakur,Carolyn Bedi,Kim Benstead,D. Bloomfield,Rebecca Bowen,Chris Bradley,Jane Brown,Mohammad Butt,Mark Churn,Susan Cleator,Joanne Cliff,Perric Crellin,Margaret Daly,Shiroma De Silva-Minor,A.S. Dhadda,O.S. Din,Sue Down,H. M. Earl,David J. Eaton,Andrew Eichholz,Daniel Epurescu,Chee Goh,Andrew D. Goodman,Robert Grieve,Maher Hadaki,Catherine Harper-Wynne,Larry Hayward,A. Humphreys,Helen Innes,Mariam Jafri,Apurna Jegannathen,Muireann Kelleher,Hartmut Kristeleit,Daniela Lee,Susan Lupton,Carol MacGregor,Zafar Malik,Jennifer Marshall,Trevor McGolick,Rakesh Mehra,Natasha Mithal,Charlotte Moss,Aian Moss,Mukesh Mukesh,Anthony Neal,Daniel Nelmes,Helen Neville-Webbe,Jacqueline Newby,S O'Reilly,Peter Ostler,Mojca Persic,Laura Pettit,Fharat A. Raja,Catherine Reed,Anne Rigg,Helen Roe,Nihal Shah,Peter Simmonds,Eliot Sims,Sarah Smith,Nicola Storey,Wendy Taylor,Narottam Thanvi,Karen Tipples,Jayant S. Vaidya,Mohini Varughese,Anup Vinayan,Nawaz Walji,Simon Waters,Kathryn Wright,Sundus Yahya +117 more
TL;DR: 6-month trastuzumab treatment is shown to be non-inferior to 12-month treatment in patients with HER2-positive early breast cancer, with less cardiotoxicity and fewer severe adverse events, which support consideration of reduced duration trastzumab for women at similar risk of recurrence as to those included in the trial.
Journal ArticleDOI
p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels.
N. Gopalakrishna Iyer,Suet-Feung Chin,Hilal Özdağ,Yataro Daigo,De-En Hu,Massimiliano Cariati,Kevin M. Brindle,Samuel Aparicio,Carlos Caldas +8 more
TL;DR: It is shown that the E1A-binding p300 nucleoprotein is a key determinant of p53-dependent cell fate in colorectal cancer cells: absence of p300 increases apoptosis in response to DNA damage and suggests that p300 inhibition could be used to modulate chemotherapy.
Journal ArticleDOI
K-ras mutation and pancreatic adenocarcinoma.
Carlos Caldas,Scott E. Kern +1 more
TL;DR: K-ras mutations are a defining event in pancreatic ductal carcinogenesis and can be a molecular target for therapeutic intervention, as illustrated with the use of farnesylation inhibitors.
Journal ArticleDOI
Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays.
Grace Callagy,Paul D.P. Pharoah,Suet-Feung Chin,Trogon Sangan,Yataro Daigo,Lucy Jackson,Carlos Caldas +6 more
TL;DR: The results indicate that the complementary use of array‐CGH and tissue microarrays has the potential to help in the identification and validation of molecular markers that can be used to classify breast cancers into different prognostic groups.